CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it has dosed the first patient in a Phase 2a proof of concept clinical trial in Type 2 diabetes with CRx-401, a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain.
